Jim Beitel

Mr. Beitel is Senior Vice President, Corporate Development, at Fate Therapeutics and is responsible for developing and implementing strategic growth initiatives including expanding the company’s induced pluripotent stem cell (iPSC)-derived cell therapy pipeline through corporate partnerships. Mr. Beitel has more than 20 years of leadership experience in corporate development, strategy, sales and marketing, project management, and finance with experience across the spectrum of life science companies. Mr. Beitel was previously Vice President of Corporate Development and Operations at Avanir Pharmaceuticals, where he facilitated the company’s growth into a multi-product organization and the subsequent acquisition of Avanir by Otsuka. Prior to Avanir, Mr. Beitel held various business development, sales and marketing, strategy, and finance roles with increasing responsibility at Amgen, La Jolla Pharmaceutical Company, and Zacharon Pharmaceuticals. Mr. Beitel holds a Master in Business Administration from Harvard Business School and a Bachelor of Science in Engineering from the University of Kansas.